Welcome to the DeBosch lab

The DeBosch laboratory uses mouse genetic, physiological, cell biological and multi-omic techniques to understand the signaling pathways that are activated downstream of blocking hepatocyte glucose transporters.

We found that inhibiting hepatocyte glucose transport and the adaptive responses that are engaged are sufficient to convey key aspects of the physiological response to caloric restriction.  This includes upregulation of hepatic fat oxidation, autophagy and secretion of the anti-diabetic peptide — FGF21.  Our goal is to understand and then utilize these responses to treat metabolic diseases, including non-alcoholic fatty liver disease, cardiovascular disease and type 2 diabetes mellitus. 

Join us

We are always interested in having people join our team.

Sample photo from article

Principal Investigator

Brian DeBosch, MD, PhD

Brian DeBosch, MD, PhD received his undergraduate degree from the University of Michigan, Ann Arbor and did his medical and graduate training as part of the Medical Scientist Training Program at Washington University School of Medicine, during which he completed his doctoral thesis in the laboratory of Anthony Muslin, MD studying signaling pathways involved cardiac hypertrophy. After MSTP training, DeBosch completed pediatrics residency and gastroenterology fellowship as part of the Accelerated Research Pathway at St. Louis Children’s Hospital. In July 2011, DeBosch pursued post-doctoral training as a Pediatric Scientist Development Program (PSDP) Fellow in the laboratory of Kelle Moley, MD in the Women’s Health Science Research Center at Washington University School of Medicine.

DeBosch is currently an Associate Professor in the Departments of Pediatrics and Cell Biology & Physiology at Washington University School of Medicine, where he studies the role of hexose transport and hexose-induced signaling events in dictating hepatic metabolism. He maintains a particular interest in how manipulating hexose metabolism applies to the prevention and treatment of non-alcoholic fatty liver disease and metabolic syndrome in both children and adults.